

Efficacy and safety of tolterodine in patients with detrusor study

BJU International

81, 42-48

DOI: [10.1046/j.1464-410x.1998.00501.x](https://doi.org/10.1046/j.1464-410x.1998.00501.x)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 529-539. | 2.3 | 121 |
| 2 | Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. <i>BJU International</i> , 1998, 81, 801-810. | 1.3 | 368 |
| 3 | OFFICE MANAGEMENT OF FEMALE URINARY INCONTINENCE. <i>Urologic Clinics of North America</i> , 1998, 25, 625-645. | 0.8 | 10 |
| 4 | Tolterodine. <i>Drugs</i> , 1998, 55, 813-820. | 4.9 | 155 |
| 5 | Tolterodine Use for Symptoms of Overactive Bladder. <i>Annals of Pharmacotherapy</i> , 1999, 33, 1073-1082. | 0.9 | 34 |
| 6 | Tolterodine: a new antimuscarinic agent for the treatment of the overactive bladder. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1073-1078. | 1.9 | 6 |
| 7 | Muscarinic receptor ligands and their therapeutic potential. <i>Current Opinion in Chemical Biology</i> , 1999, 3, 426-432. | 2.8 | 106 |
| 8 | Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 553-563. | 1.1 | 38 |
| 9 | Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 564-572. | 1.1 | 40 |
| 10 | Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 145-150. | 1.1 | 21 |
| 11 | Clinical Efficacy and Safety of Tolterodine Compared to Oxybutynin and Placebo in Patients with Overactive Bladder. <i>International Urogynecology Journal</i> , 1999, 10, 283-289. | 0.7 | 208 |
| 12 | Tolterodine, a New Antimuscarinic Drug for Treatment of Bladder Overactivity. <i>Pharmacotherapy</i> , 1999, 19, 267-280. | 1.2 | 37 |
| 13 | Serum protein binding of tolterodine and its major metabolites in humans and several animal species. , 1999, 20, 91-99. | | 48 |
| 14 | CLINICAL EFFICACY AND SAFETY OF TOLTERODINE COMPARED TO PLACEBO IN DETRUSOR OVERACTIVITY. <i>Journal of Urology</i> , 1999, 161, 1551-1555. | 0.2 | 144 |
| 15 | MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER. <i>BJU International</i> , 2000, 85, 33-46. | 1.3 | 7 |
| 16 | Reproducibility of Cystometry in Overactive Detrusor. <i>European Urology</i> , 2000, 38, 681-685. | 0.9 | 35 |
| 17 | Treatment of urinary incontinence. <i>Current Urology Reports</i> , 2000, 1, 235-244. | 1.0 | 2 |
| 18 | Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin. <i>BJU International</i> , 2000, 86, 44-54. | 1.3 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Enuresis - Background and Treatment. Scandinavian Journal of Urology and Nephrology, 2000, 34, 1-44. | 1.4 | 102 |
| 20 | Advances in Managing Overactive Bladder. Journal of Pharmacy Practice, 2000, 13, 277-289. | 0.5 | 0 |
| 21 | Advancements in pharmacologic management of the overactive bladder. Urology, 2000, 56, 41-49. | 0.5 | 52 |
| 22 | Muscarinic receptor antagonists in the treatment of overactive bladder. Urology, 2000, 55, 33-46. | 0.5 | 260 |
| 23 | Tolterodine, an Effective and Well Tolerated Treatment for Urge Incontinence and Other Overactive Bladder Symptoms. Clinical Drug Investigation, 2000, 19, 83-91. | 1.1 | 61 |
| 24 | Tolterodine. Drugs and Aging, 2001, 18, 277-304. | 1.3 | 90 |
| 25 | Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 98, 97-102. | 0.5 | 48 |
| 26 | TOLTERODINE: SUPERIOR TOLERABILITY THAN AND COMPARABLE EFFICACY TO OXYBUTYNYN IN INDIVIDUALS 50 YEARS OLD OR OLDER WITH OVERACTIVE BLADDER: A RANDOMIZED CONTROLLED TRIAL. Journal of Urology, 2001, 165, 1452-1456. | 0.2 | 127 |
| 27 | Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study. Mayo Clinic Proceedings, 2001, 76, 358-363. | 1.4 | 107 |
| 28 | USE OF TOLTERODINE IN CHILDREN WITH DYSFUNCTIONAL VOIDING: AN INITIAL REPORT. Journal of Urology, 2001, 165, 926-928. | 0.2 | 34 |
| 29 | Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study. Mayo Clinic Proceedings, 2001, 76, 358-363. | 1.4 | 227 |
| 30 | Pharmacological Management of Detrusor Instability. International Urogynecology Journal, 2001, 12, 271-278. | 0.7 | 7 |
| 31 | Tolterodine: A Safe and Effective Treatment for Older Patients with Overactive Bladder. Journal of the American Geriatrics Society, 2001, 49, 700-705. | 1.3 | 138 |
| 32 | The pharmacological treatment of urinary incontinence. BJU International, 2001, 84, 923-947. | 1.3 | 141 |
| 33 | Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis. American Journal of Obstetrics and Gynecology, 2001, 185, 56-61. | 0.7 | 78 |
| 34 | Tolterodine: A Clinical Review. Journal of Women's Health and Gender-Based Medicine, 2001, 10, 735-743. | 1.7 | 19 |
| 35 | Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opinion on Pharmacotherapy, 2001, 2, 1685-1701. | 0.9 | 32 |
| 36 | Drug Therapy of Urinary Urge Incontinence. Obstetrics and Gynecology, 2002, 100, 1003-1016. | 1.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. , 2002, , CD003781. | | 35 |
| 39 | Muscarinic receptor subtypes and management of the overactive bladder. <i>Urology</i> , 2002, 60, 82-88. | 0.5 | 117 |
| 40 | Drug therapy of urinary urge incontinence: a systematic review. <i>Obstetrics and Gynecology</i> , 2002, 100, 1003-1016. | 1.2 | 39 |
| 41 | Pharmacologic management of urinary incontinence in women. <i>Urologic Clinics of North America</i> , 2002, 29, 537-550. | 0.8 | 15 |
| 42 | Once-Daily, Extended-Release Formulations of Antimuscarinic Agents in the Treatment of Overactive Bladder: A Review. <i>European Urology</i> , 2002, 41, 6-14. | 0.9 | 71 |
| 43 | Management of Parkinson's disease: An evidence-based review. <i>Movement Disorders</i> , 2002, 17, i-i. | 2.2 | 39 |
| 44 | Voiding and incontinence frequencies: Variability of diary data and required diary length. <i>Neurourology and Urodynamics</i> , 2002, 21, 204-209. | 0.8 | 75 |
| 45 | Pharmacologic treatment for detrusor overactivity. <i>Current Urology Reports</i> , 2002, 3, 365-372. | 1.0 | 6 |
| 46 | A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. <i>BJU International</i> , 2002, 90, 375-380. | 1.3 | 33 |
| 47 | In vivo evaluation of the potency and bladder-vascular selectivity of the ATP-sensitive potassium channel openers (-) cromakalim, ZD6169 and WAY-133537 in rats. <i>BJU International</i> , 2003, 91, 284-290. | 1.3 | 29 |
| 48 | The use of tolterodine in children after oxybutynin failure. <i>BJU International</i> , 2003, 91, 398-401. | 1.3 | 57 |
| 49 | Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial. <i>Mayo Clinic Proceedings</i> , 2003, 78, 687-695. | 1.4 | 304 |
| 50 | Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1243-1285. | 1.6 | 97 |
| 51 | Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 652-656. | 1.1 | 22 |
| 52 | Darifenacin, an M3 Selective Receptor Antagonist, is an Effective and Well-Tolerated Once-Daily Treatment for Overactive Bladder. <i>European Urology</i> , 2004, 45, 420-429. | 0.9 | 219 |
| 53 | Comparison of the Efficacy of Tolterodine and Oxybutynin in Different Urodynamic Severity Grades of Idiopathic Detrusor Overactivity. <i>European Urology</i> , 2004, 46, 776-783. | 0.9 | 24 |
| 54 | Benefit-Risk Assessment of Tolterodine in the Treatment of Overactive Bladder in Adults. <i>Drug Safety</i> , 2004, 27, 1043-1057. | 1.4 | 19 |
| 55 | Efficacy and Safety of Tol Terodine in People With Neurogenic Detrusor Overactivity. <i>Journal of Spinal Cord Medicine</i> , 2004, 27, 214-218. | 0.7 | 61 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 56 | Variability of detrusor overactivity on repeated filling cystometry in men with urge symptoms: comparison with spinal cord injury patients. <i>BJU International</i> , 2005, 95, 587-590. | 1.3 | 39 |
| 57 | Comparison of Dry Mouth in Women Treated with Extended-Release Formulations of Oxybutynin or Tolterodine for Overactive Bladder. <i>International Urology and Nephrology</i> , 2005, 37, 247-252. | 0.6 | 22 |
| 58 | Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2005, 120, 129-133. | 0.5 | 8 |
| 59 | Which anticholinergic drug for overactive bladder symptoms in adults. , 2005, , CD005429. | | 77 |
| 60 | The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 509-527. | 0.9 | 7 |
| 61 | Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. <i>The Cochrane Library</i> , 2006, , CD003781. | 1.5 | 215 |
| 62 | The effects of antimuscarinics on health-related quality of life in overactive bladder: A systematic review and meta-analysis. <i>Urology</i> , 2006, 68, 38-48. | 0.5 | 85 |
| 63 | Assessment of treatment outcomes in patients with overactive bladder: Importance of objective and subjective measures. <i>Urology</i> , 2006, 68, 17-28. | 0.5 | 76 |
| 64 | Overactive Bladder: Pharmacologic Therapy. , 2006, , 169-174. | | 1 |
| 65 | Overactive Bladder Syndrome: Considerations in Pharmacotherapy and New Perspectives. <i>Gynakologisch-geburtshilfliche Rundschau</i> , 2006, 46, 83-87. | 0.9 | 1 |
| 66 | Pharmacological Treatment for Overactive Bladder in Women. <i>Women's Health</i> , 2006, 2, 239-250. | 0.7 | 0 |
| 67 | Management of overactive bladder syndrome. <i>Postgraduate Medical Journal</i> , 2007, 83, 481-486. | 0.9 | 35 |
| 68 | Thorough QT Study with Recommended and Supratherapeutic Doses of Tolterodine. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 377-385. | 2.3 | 81 |
| 69 | Number of Daytime Micturitions and Volume Voided per Micturition in the Evaluation of Efficacy of Drugs for Overactive Bladder: Findings from Randomized Clinical Trials. <i>European Urology</i> , 2007, 52, 525-530. | 0.9 | 13 |
| 70 | A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder. <i>European Urology</i> , 2008, 54, 740-764. | 0.9 | 228 |
| 71 | Tolterodine for the treatment of overactive bladder. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1249-1255. | 0.9 | 17 |
| 72 | Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-controlled, Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants ≥ 50 Years. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2008, 13, 241-251. | 1.0 | 63 |
| 73 | Pharmacotherapy of overactive bladder syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 163-175. | 1.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 74 | DRUG TREATMENT OF URINARY INCONTINENCE IN WOMEN. , 2008, , 233-256. | | 0 |
| 75 | Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction. <i>Advances in Urology</i> , 2009, 2009, 1-10. | 0.6 | 11 |
| 76 | A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. <i>BMC Medical Research Methodology</i> , 2009, 9, 55. | 1.4 | 54 |
| 77 | Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjectsâ€”A placebo controlled double blind investigation using 4 and 8â€”mg tolterodine extended release. <i>Neurourology and Urodynamics</i> , 2010, 29, 464-469. | 0.8 | 4 |
| 80 | Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin. <i>Clinical Pharmacokinetics</i> , 2009, 48, 281-302. | 1.6 | 54 |
| 81 | Comparison of Outcome Assessments in Patients with Overactive Bladder Receiving Anticholinergics. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, 40-44. | 0.6 | 0 |
| 82 | Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst womenâ€”a randomized controlled trial. <i>International Urogynecology Journal</i> , 2010, 21, 1517-1524. | 0.7 | 19 |
| 83 | New drug treatments for urinary incontinence. <i>Maturitas</i> , 2010, 65, 340-347. | 1.0 | 21 |
| 84 | Adverse Event Assessment of Antimuscarinics for Treating Overactive Bladder: A Network Meta-Analytic Approach. <i>PLoS ONE</i> , 2011, 6, e16718. | 1.1 | 119 |
| 85 | The placebo effect in overactive bladder syndrome. <i>Nature Reviews Urology</i> , 2011, 8, 495-503. | 1.9 | 43 |
| 87 | Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women. <i>Annals of Internal Medicine</i> , 2012, 156, 861. | 2.0 | 88 |
| 88 | Efficacy and Adverse Events of Antimuscarinics for Treating Overactive Bladder: Network Meta-analyses. <i>European Urology</i> , 2012, 62, 1040-1060. | 0.9 | 143 |
| 89 | Phase IIb, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Determine Effects of Elocalcitol in Women With Overactive Bladder and Idiopathic Detrusor Overactivity. <i>Urology</i> , 2012, 80, 48-54. | 0.5 | 43 |
| 90 | Which anticholinergic drug for overactive bladder symptoms in adults. <i>The Cochrane Library</i> , 2012, 1, CD005429. | 1.5 | 146 |
| 92 | Does Conservative Management Really Benefit Patients with OAB?. <i>Current Urology Reports</i> , 2012, 13, 348-355. | 1.0 | 4 |
| 93 | A formulation approach for development of HPMC-based sustained release tablets for tolterodine tartrate with a low release variation. <i>Drug Development and Industrial Pharmacy</i> , 2013, 39, 1720-1730. | 0.9 | 13 |
| 94 | Cardiovascular effects of antimuscarinic agents in overactive bladder. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 815-827. | 1.0 | 25 |
| 95 | Medical Therapy in Overactive Bladder of the Elderly. <i>Current Bladder Dysfunction Reports</i> , 2014, 9, 326-335. | 0.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 96 | Nonsurgical Management of Urinary Incontinence in Women: A Clinical Practice Guideline From the American College of Physicians. <i>Annals of Internal Medicine</i> , 2014, 161, 429. | 2.0 | 122 |
| 97 | Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women. <i>Obstetrics and Gynecology</i> , 2015, 125, 1423-1432. | 1.2 | 60 |
| 98 | Overactive bladder " 18 years " Part II. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2016, 42, 199-214. | 0.7 | 13 |
| 99 | Physiotherapy and behavior therapy for the treatment of overactive bladder syndrome: a prospective cohort study. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1211-1217. | 0.8 | 8 |
| 100 | Simultaneous determination of tolterodine and its two metabolites, 5-hydroxymethyltolterodine and N-dealkyltolterodine in human plasma using LC-MS/MS and its application to a pharmacokinetic study. <i>Archives of Pharmacal Research</i> , 2017, 40, 1287-1295. | 2.7 | 4 |
| 102 | The Management of Urine Storage Dysfunction in the Neurological Patient. <i>SN Comprehensive Clinical Medicine</i> , 2019, 1, 160-182. | 0.3 | 7 |
| 103 | Incontinence in the elderly. <i>Current Opinion in Obstetrics and Gynecology</i> , 1998, 10, 391-394. | 0.9 | 3 |
| 104 | CLINICAL EFFICACY AND SAFETY OF TOLTERODINE COMPARED TO PLACEBO IN DETRUSOR OVERACTIVITY. <i>Journal of Urology</i> , 1999, , 1551-1555. | 0.2 | 8 |
| 105 | USE OF TOLTERODINE IN CHILDREN WITH DYSFUNCTIONAL VOIDING: AN INITIAL REPORT. <i>Journal of Urology</i> , 2001, , 926-928. | 0.2 | 1 |
| 106 | TOLTERODINE: SUPERIOR TOLERABILITY THAN AND COMPARABLE EFFICACY TO OXYBUTYNYN IN INDIVIDUALS 50 YEARS OLD OR OLDER WITH OVERACTIVE BLADDER: A RANDOMIZED CONTROLLED TRIAL. <i>Journal of Urology</i> , 2001, , 1452-1456. | 0.2 | 8 |
| 107 | Overactive detrusor. <i>Current Opinion in Urology</i> , 1999, 9, 291-296. | 0.9 | 2 |
| 108 | Validation of the Differential Cardiovascular Effects of the Antimuscarinic Agents Darifenacin and Tolterodine in a Randomized, Placebo-Controlled, 3-Way Crossover Study. <i>UroToday International Journal</i> , 2009, 02, . | 0.1 | 5 |
| 109 | The newer antimuscarinic drugs: bladder control with less dry mouth.. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, 761-761. | 0.6 | 20 |
| 111 | <i>Urologika</i> . , 2001, , 639-658. | | 0 |
| 112 | <i>Pharmakotherapie der Dranginkontinenz</i> . , 2002, , 249-267. | | 0 |
| 113 | <i>Assessment and Treatment of Urinary Incontinence in Neurologically Impaired Patients</i> . , 2002, , 23-37. | | 0 |
| 114 | <i>Urologika</i> . , 2003, , 734-755. | | 0 |
| 115 | <i>Overactive Bladder Syndrome and Nocturia</i> . , 2007, , 353-376. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 116 | Molecular Modelling Analysis of the Metabolism of Tolterodine. Journal of Pharmacology and Toxicology, 2007, 2, 319-329. | 0.4 | 1 |
| 117 | Overactive Bladder. , 2008, , 246-252. | | 0 |
| 118 | SÃndrome de vejiga hiperactiva y nicturia. , 2008, , 363-385. | | 0 |
| 120 | The Placebo Effect in Overactive Bladder Syndrome. , 2019, , 27-45. | | 0 |
| 122 | Overactive Bladder: Pharmacologic Therapy. , 2008, , 169-174. | | 0 |
| 123 | Tolterodine in the Treatment of Clozapine-Associated Urinary Incontinence. Journal of Clinical Psychopharmacology, 2020, 40, 634-635. | 0.7 | 4 |
| 124 | Selecting a medical therapy for overactive bladder. Reviews in Urology, 2002, 4 Suppl 4, S28-37. | 0.9 | 3 |
| 125 | Recent clinical studies of new pharmacologic agents and their efficacy in the treatment of incontinence. Reviews in Urology, 2001, 3 Suppl 1, S15-8. | 0.9 | 2 |